Recurrences of Clostridium difficile infections lead to hospital readmissions 
and high costs, in addition to the suffering and frustration for the patients. 
Fidaxomicin has recently been introduced as a new antibiotic that has been shown 
to significantly reduce the recurrence of this infection. Despite this 
superiority, its high cost has led to very restrictive policies in its use, as 
such that many institutions only use it in patients with multiple recurrences. 
While waiting for new predictive clinical tools, we propose the development of 
scoring systems that allow the more high-risk patients to be treated earlier.